Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Capital Expenditures (2017 - 2026)

Cogent Biosciences' Capital Expenditures history spans 9 years, with the latest figure at $449000.0 for Q1 2026.

  • Quarterly Capital Expenditures fell 17.92% to $449000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2026, up 38.67% year-over-year, with the annual reading at $1.6 million for FY2025, 171.2% up from the prior year.
  • Capital Expenditures came in at $449000.0 for Q1 2026, down from $811000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.3 million in Q3 2022 to a low of $65000.0 in Q3 2025.
  • The 5-year median for Capital Expenditures is $441000.0 (2022), against an average of $719705.9.
  • Year-over-year, Capital Expenditures tumbled 96.35% in 2023 and then surged 981.33% in 2025.
  • Cogent Biosciences' Capital Expenditures stood at $2.0 million in 2022, then tumbled by 83.99% to $315000.0 in 2023, then tumbled by 76.19% to $75000.0 in 2024, then soared by 981.33% to $811000.0 in 2025, then tumbled by 44.64% to $449000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Capital Expenditures are $449000.0 (Q1 2026), $811000.0 (Q4 2025), and $65000.0 (Q3 2025).